Vyne Therapeutics Inc expected to post a loss of $2.61 a share - Earnings Preview

YARROW BIOSCIENCE

08/05/2023 12:38

* Vyne Therapeutics Inc  VYNE.OQ   VYNE.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 10
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Vyne Therapeutics
Inc is
for a loss of $2.61 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 3.8%
in the last three months. ​
    * Wall Street's median 12-month price target for Vyne
Therapeutics
Inc is $72​, above​ its last closing price of $7.96. ​​​

This summary was machine generated May 8 at 11:38 GMT.  All
figures in US dollars  unless otherwise stated